| Cat.No. | Name | Information |
|---|---|---|
| M3030 | S-Ruxolitinib | S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M1820 | Tofacitinib | Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM. |
| M1660 | AZ 960 | AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro. |
| M1646 | AG490 | AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). |
| M1733 | TG101348 | TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. |
| M1787 | INCB18424 | INCB18424 is a potent inhibitor of both JAK1 and JAK2 with selectivity versus JAK3 and TYK2 (IC50 values of 2.7, 4.5, 332, and 19 nM, respectively, in biochemical assays). |
| M5944 | Ruxolitinib phosphate | Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M3616 | Tofacitinib citrate | Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| M2346 | Filgotinib | Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively. |
| M2044 | AZD1480 | AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively. |
| M1804 | NVP-BSK805 dihydrochloride | NVP-BSK805 dihydrochloride is a potent and selective quinoxaline JAK2 inhibitor with IC50 values of 0.48, 0.56 and 0.58 nM for JAK2 JH1, FL JAK V617F and FL JAK2 wt respectively. |
| M1754 | WP1130 | Degrasyn (WP1130) is a small molecular deubiquitinase (DUB) inhibitor and suppresses JAK-Stat signaling pathway. |
| M1700 | Momelotinib (CYT387) | Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. |
| M40851 | SDC-1802 | SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus. |
| M40850 | OST-246 | OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation. |
| M40849 | NDI-031232 | NDI-031232 is a TYK2 inhibitor. |
| M40848 | NDI-031301 | NDI-031301 is a TYK2 inhibitor. |
| M40847 | NDI-031407 | NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis. |
| M40846 | A2A-I-01 | A2A-I-01 is a TYK2 inhibitor that can be used in studies related to autoimmune diseases. |
| M40840 | GLPG3121 | GLPG3121 is a JAK1/TYK2 inhibitor that can be used in studies related to inflammation and psoriasis. |
| M40839 | SDC-1801 | SDC-1801 is a JAK1/TYK2 inhibitor that can be used in studies related to inflammatory bowel disease, multiple sclerosis, and psoriasis. |
| M40837 | BGB-23339 | BGB-23339 is a highly selective TYK2 variant inhibitor for studies related to autoimmune diseases. |
| M40836 | ABBV-712 | ABBV-712 is a TYK2 inhibitor that can be used in studies related to psoriasis. |
| M40835 | OST-122 | OST-122 is a JAK3/SYK2/ARK5 multi-target inhibitor for ulcerative colitis related studies. |
| M40834 | VTX-958 | VTX-958 is an allosteric TYK2 inhibitor that can be used in studies related to psoriasis. |
| M40833 | GLPG3667 | GLPG3667 is a selective tyrosine kinase 2 (TYK2) inhibitor for studies related to systemic lupus erythematosus and psoriasis. |
| M40831 | ESK-001 | ESK-001 is a highly selective and potentially first-in-class heterotrimeric tyrosine kinase 2 (TYK2) inhibitor for studies related to systemic lupus erythematosus (SLE). |
| M40829 | BMS-986322 | BMS-986322 is a TYK2 inhibitor that may be used in studies related to psoriasis. |
| M40753 | Ritlecitinib tosylate | Ritlecitinib tosylate is a first-in-class, orally active, dual covalent inhibitor of tyrosine kinases in the JAK3 and TEC families. The IC50 for JAK3 is 33.1 nM and there is no activity against JAK1, JAK2 and TYK2. |
| M30102 | Coumermycin A1 | Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
